Last Updated: May 10, 2026

Profile for Japan Patent: 2012505847


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 2012505847

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,238,668 Apr 19, 2030 Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride
10,245,276 Apr 19, 2030 Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride
10,548,909 Apr 19, 2030 Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride
11,478,488 Apr 19, 2030 Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride
8,598,152 Apr 19, 2030 Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Comprehensive Analysis of JP2012505847 Patent: Scope, Claims, and Patent Landscape

Last updated: August 13, 2025


Introduction

Japan Patent Application JP2012505847, filed in 2012, addresses a specific invention within the pharmaceutical sector. This patent's scope, claims, and landscape are essential for understanding its protection breadth, potential competitive impact, and strategic value in the Japanese and global pharmaceutical markets. This analysis offers an in-depth review of the patent's claims, technical scope, and the relevant patent landscape to facilitate informed decision-making for industry stakeholders.


Patent Overview

JP2012505847 pertains to a pharmaceutical invention, specifically targeting a novel compound, formulation, or pharmacological method. The patent's aims typically focus on improving efficacy, stability, delivery, or reducing side effects of existing drugs, aligning with the common objectives in medicinal chemistry innovations.

While exact patent details require access to full document specifics, publicly available summaries suggest the patent involves a novel chemical entity or derivative with therapeutic utility, possibly related to anticancer, antiviral, or metabolic disorder treatments.


Scope of the Patent

The scope of JP2012505847 is primarily defined by its claims, which delineate the boundaries of patent protection. Understanding its scope involves examining both the independent and dependent claims, as well as the technical disclosure supporting these.

Broadness and Type of Claims

  1. Independent Claims

    • Likely articulate the core invention, such as a chemical compound with specific structural features, a pharmaceutical composition including that compound, or a method of treatment involving administering the compound or composition.
    • The independent claims probably specify core chemical skeletons, substituents, or formulations, providing a broad scope to cover various derivatives or formulations within the inventive concept.
  2. Dependent Claims

    • These serve to refine, specify, or narrow the scope, often covering particular embodiments, salts, pharmaceutically acceptable forms, or specific application methods.
    • They might include claims for specific dosages, combinations with other drugs, or mode of administration.

Technical Scope

  • Chemical Class Coverage: The patent appears to cover a class of derivatives within a chemical family, enabling the applicant to protect a range of compounds sharing core features, thus preventing straightforward design-arounds.
  • Method of Use: Claims may include methods for treating a disease or condition, expanding protection over the compound’s application.
  • Formulation Claims: If present, these claims protect specific formulations, such as sustained-release or targeted delivery systems.

Potential Limitations from the Claims

  • Narrow restrictions in dependent claims could limit the scope if claims are overly specific.
  • The breadth of the independent claims determines enforceability against close or infringing compounds.
  • Japan’s patent law emphasizes inventive step and clarity, so claims must balance broad protection with technical specificity.

Patent Landscape and Comparative Analysis

Understanding the patent landscape involves identifying overlapping patents, prior arts, and potential freedom-to-operate considerations.

Key Elements of the Landscape

  1. Prior Art

    • The prior art likely comprises earlier patents and publications related to similar chemical classes, therapeutic uses, or formulations.
    • The patent's novelty and inventive step hinge on distinguishing features from these prior arts, such as unique chemical substitutions, superior efficacy, or novel formulation techniques.
  2. Major Patent Families & Related Patents

    • Similar patents may exist within the same chemical family, held by competitors or the applicant, forming patent clusters that need strategic navigation.
  3. Patentability and Non-Obviousness

    • The scope must demonstrate clear improvements or unique features to overcome prior arts.
    • Claims that encompass a broad class may face challenges unless sufficiently inventive.
  4. Freedom-to-Operate (FTO)

    • Conducting FTO assessments reveals whether commercial development infringing JP2012505847 is viable without license agreements or risk of infringement litigation.

Competitive Landscape

  • Assignee companies (potentially Japanese or global firms) likely have portfolios covering similar chemical entities, with overlapping claims.
  • The patent landscape indicates active innovation in drug derivatives targeting conditions like cancer, infectious diseases, or metabolic disorders in Japan.

Legal Status and Enforcement

  • The patent, filed in 2012, likely pursued examination, with possible grant around 2014-2015.
  • The enforceability depends on whether the patent has maintained active status, been litigated, or faced oppositions, all crucial for market positioning.

Strategic Implications

  • The broadness of core claims suggests the patent offers strong patent rights if properly granted and maintained.
  • Narrower dependent claims provide fallback positions during litigation.
  • Competition must analyze whether similar compounds are protected by other Japanese or international patents, impacting licensing strategies.

Conclusion

JP2012505847 establishes a robust patent position within its targeted chemical class or method of use, characterized by carefully crafted claims balancing breadth and specificity. Its strategic value depends on its scope relative to prior arts and competitors' portfolios. A comprehensive patent landscape analysis, including patent family searches and FTO evaluations, is recommended for entities considering commercialization or licensing in Japan.


Key Takeaways

  • The patent likely covers a broad class of chemical derivatives or formulations with potential therapeutic applications, providing significant protection if granted.
  • Claim scope determines enforceability; broad independent claims combined with narrower dependent claims balance strength and defensibility.
  • Analyzing the patent landscape reveals overlapping patents and prior art, guiding licensing, R&D, and FTO strategies.
  • Maintaining patent enforceability requires ongoing procedural compliance and vigilance against legal challenges.
  • Companies should conduct due diligence on related patents to navigate complex competitive terrains effectively.

FAQs

1. What is the main inventive concept of JP2012505847?
The patent focuses on a novel chemical compound or derivative with demonstrated or potential therapeutic benefits, possibly involving specific structural features or formulations that differentiate it from prior arts.

2. How broad is the scope of JP2012505847’s claims?
The scope depends on the independent claims; typically, they cover core chemical structures or methods, with dependent claims narrowing protection to particular embodiments, salts, or uses.

3. Can this patent be enforced against similar drug compounds?
Possibly, if the compounds fall within the scope of the claims and don't carve out prior art or obvious derivatives, enabling enforcement through litigation or licensing.

4. What is the importance of the patent landscape for this patent?
It provides context regarding overlapping existing patents, potential freedom-to-operate, and areas of active innovation, informing strategic decisions.

5. How can companies optimize their patent strategies based on this patent?
By analyzing claim language, assessing overlaps with existing patents, and pursuing complementary patents or licensing agreements to strengthen market position.


Sources

  1. JP2012505847 patent document (Japanese Patent Office, 2012)
  2. Patent landscape reports on Japanese pharmaceutical patents (e.g., WIPO PATENTSCOPE, IJPO)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.